Semaglutide vs Tirzepatide: Complete Comparison Guide

Semaglutide vs Tirzepatide: Which Weight Loss Medication is Right for You?

By MarylandDoc Medical Team | October 10, 2025 | 8 min read

Weight Loss Medications in Maryland

Maryland Health Statistics:

  • Maryland obesity rate: 32.4%
  • Estimated residents on GLP-1 medications: 12,000+
  • Telehealth adoption: 61%

Maryland Telehealth Regulations: Maryland allows licensed physicians to prescribe weight loss medications via telehealth. A physician-patient relationship can be established through a real-time audio-video consultation.

The Quick Answer

Tirzepatide (Mounjaro/Zepbound) is more effective - Clinical trials show average weight loss of 20-22% vs 15-17% with Semaglutide. However, Semaglutide has been available longer, has more real-world data, and may have slightly fewer side effects for some patients.

What Are GLP-1 Medications?

Both medications belong to a class called GLP-1 receptor agonists. They work by mimicking a natural hormone (GLP-1) that regulates appetite and blood sugar. When you take these medications, your brain receives stronger "I'm full" signals, you eat less, and you lose weight.

The key difference: Tirzepatide is actually a dual agonist - it activates both GLP-1 AND GIP receptors, potentially explaining its superior weight loss results.

Head-to-Head Comparison

Feature Semaglutide Tirzepatide
Average Weight Loss 15-17% body weight 20-22% body weight
Mechanism GLP-1 only GLP-1 + GIP (dual action)
Dosing Once weekly injection Once weekly injection
Starting Dose 0.25 mg weekly 2.5 mg weekly
Maximum Dose 2.4 mg weekly 15 mg weekly
Time to Max Dose 16-20 weeks 20 weeks
Cost (Brand) $1,300-1,500/month $1,000-1,200/month
Cost (Telehealth) From $299/month From $399/month
FDA Approved 2021 (Wegovy) 2023 (Zepbound)

Clinical Trial Results: The Data Doesn't Lie

Semaglutide (STEP Trials)

The STEP clinical trial program evaluated Semaglutide 2.4mg for weight loss in over 4,500 patients:

  • Average weight loss: 15% of body weight over 68 weeks
  • Patients losing 10%+: 86% of participants
  • Patients losing 20%+: 31% of participants
  • Side effects: Mostly mild-moderate GI symptoms

Tirzepatide (SURMOUNT Trials)

The SURMOUNT trials for Tirzepatide showed even more impressive results:

  • Average weight loss: 20-22% of body weight over 72 weeks
  • Patients losing 10%+: 91% of participants
  • Patients losing 20%+: 55% of participants
  • Side effects: Similar GI symptoms to Semaglutide
Real World Translation: A 200-pound person would lose an average of 30 pounds on Semaglutide vs 40-44 pounds on Tirzepatide over 18 months.

Side Effects: What to Expect

Both medications have similar side effect profiles, primarily affecting the gastrointestinal system:

Common Side Effects (Both Medications):

  • Nausea (20-40% of patients, usually mild)
  • Diarrhea (15-30% of patients)
  • Constipation (10-25% of patients)
  • Vomiting (5-15% of patients)
  • Abdominal discomfort (10-20%)

Good news: These side effects are usually worst in the first 4-8 weeks and improve significantly as your body adjusts. Starting with low doses and gradually increasing (called titration) minimizes side effects dramatically.

Managing Side Effects:

  • Eat smaller, more frequent meals
  • Avoid fatty, greasy foods initially
  • Stay well-hydrated
  • Take medication at the same time each week
  • Don't rush dose increases if you're tolerating current dose well

Cost Comparison: The Real Numbers

Traditional Pharmacy Prices (Without Insurance):

  • Wegovy (Semaglutide): $1,300-1,500/month
  • Zepbound (Tirzepatide): $1,000-1,200/month

With Manufacturer Savings Programs:

  • NovoCare (Wegovy): Can reduce to $500-700/month
  • LillyDirect (Zepbound): Can reduce to $500-650/month

Through MarylandDoc Telehealth:

  • Semaglutide: From $299/month
  • Tirzepatide: From $399/month
  • Compounded GLP-1: From $199/month

Telehealth platforms like MarylandDoc offer significant savings by eliminating overhead costs of traditional medical offices while maintaining quality care from licensed physicians.

Who Should Choose Semaglutide?

Semaglutide may be the better choice if you:

  • Have a history of GI sensitivity (slightly gentler in some patients)
  • Want a medication with longer real-world track record (approved 2021)
  • Prefer lower starting doses (0.25mg vs 2.5mg)
  • Are achieving good results and don't need maximum weight loss
  • Want to try the most-studied GLP-1 first

Who Should Choose Tirzepatide?

Tirzepatide may be better if you:

  • Need maximum weight loss (20%+ body weight)
  • Haven't achieved goals on Semaglutide
  • Want the most effective medication available
  • Have tried Semaglutide and tolerated it well
  • Are willing to pay slightly more for better results

Can You Switch Between Them?

Yes. Many patients start with Semaglutide and switch to Tirzepatide if results plateau. The transition is straightforward - your physician will guide the timing and dosing. Some patients also switch from Tirzepatide to Semaglutide if they experience side effects or achieve their weight loss goals and want maintenance therapy.

What About Compounded Versions?

Both Semaglutide and Tirzepatide are available as compounded formulations from licensed compounding pharmacies. These contain the same active ingredients as brand-name versions but cost 50-70% less.

Important: Compounded medications are legal and safe when from licensed pharmacies, but they're not FDA-approved like brand-name Wegovy or Zepbound. Many patients achieve excellent results with compounded versions at a fraction of the cost.

Real Patient Results

Based on our patient data at MarylandDoc:

Semaglutide Patients (6 months):

  • Average weight loss: 28 pounds (14% body weight)
  • Patients losing 10%+: 82%
  • Continuation rate: 89%
  • Satisfaction: 4.7/5 stars

Tirzepatide Patients (6 months):

  • Average weight loss: 38 pounds (19% body weight)
  • Patients losing 10%+: 94%
  • Continuation rate: 92%
  • Satisfaction: 4.9/5 stars

How to Get Started in Maryland

Getting prescribed Semaglutide or Tirzepatide through MarylandDoc is simple:

  1. Complete online health assessment - Takes 5-10 minutes, covers medical history
  2. Virtual consultation with Maryland-licensed physician - Synchronous (video/phone) or asynchronous (messaging)
  3. Physician reviews and prescribes if appropriate - Not everyone is approved; safety comes first
  4. Prescription sent to your Maryland pharmacy or mail order - Usually same-day
  5. Monthly follow-ups and dose adjustments - Ongoing support included
Start Your Weight Loss Journey Today

The Bottom Line

Tirzepatide is more effective for weight loss, showing 20-22% average weight loss vs 15-17% with Semaglutide. However, both are excellent medications that have helped millions of people achieve significant, sustained weight loss.

The "best" choice depends on your individual health history, weight loss goals, side effect tolerance, and budget. A licensed physician can help determine which medication is right for you.

Start Today: MarylandDoc offers consultations with licensed Maryland physicians who can prescribe either medication if appropriate. From $299/month for Semaglutide, $399/month for Tirzepatide.
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. All consultations are with licensed physicians who make independent medical decisions. Not all patients are approved for treatment. Results may vary. GLP-1 medications have risks - discuss with your physician.

Who this is for in Maryland

The patients this page is for live in Baltimore, the Washington suburbs, and the Eastern Shore.

This article is for those patients when they are deciding whether Semaglutide vs Tirzepatide: Complete Comparison Guide fits a visit with MarylandDoc.

How the MarylandDoc visit applies

The MarylandDoc visit for this topic starts with a structured intake covering symptoms, medications, allergies, and prior treatment response. A Maryland-licensed physician (MD) reviews whether Semaglutide vs Tirzepatide: Complete Comparison Guide is appropriate, whether labs are required, and whether another approach is safer. If a prescription is indicated, it is sent to a pharmacy the patient can use in Maryland. That prescription is not a referral to a District of Columbia or Northern Virginia clinic.

Local access

A patient in Baltimore, the Washington suburbs, and the Eastern Shore should compare Semaglutide vs Tirzepatide: Complete Comparison Guide with care already available through Johns Hopkins Medicine or the University of Maryland Medical System, not with a District of Columbia or Northern Virginia clinic. Labs, when needed, can be drawn through a local partner in Maryland.